Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Pacific Biosciences (NASDAQ:PACB) and raised the price target from $12 to $13.
August 04, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Pacific Biosciences and raised the price target from $12 to $13.
The news of Morgan Stanley maintaining an Equal-Weight rating on Pacific Biosciences and raising the price target from $12 to $13 is directly related to the company. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100